Cruijff M, Thijs C, Govaert T, Aretz K, Dinant G J, Knottnerus A
Department of General Practice, University Maastricht, The Netherlands.
Vaccine. 1999 Feb 5;17(5):426-32. doi: 10.1016/s0264-410x(98)00213-8.
We examined the relation between cigarette smoking and (1) the occurrence of influenza, (2) the efficacy of influenza vaccination and (3) the antibody response to influenza vaccination in fifteen family practices in South-Limburg, the Netherlands, during the influenza season 1991 1992. Data were used from a randomized double-blind placebo-controlled trial into the efficacy of influenza vaccination in which smoking status was measured 10 weeks after the start of the trial. A total of 1838 subjects aged 60 years or older, of whom 1531 subjects (321 smokers, 1152 non-smokers and 58 cigar/pipe smokers) who returned the smoking questionnaire and were not previously vaccinated, were used in the analyses. The main outcome measures were serological influenza (fourfold increase of antibody titre between 3 weeks and 5 months after vaccination); clinical influenza as determined by criteria of the Dutch Sentinel Stations from self reported symptoms in postal questionnaires 10 weeks and 5 months after vaccination; increases after vaccination and decreases after 5 months in logarithmic titres of antibody against the vaccine strains. No relation between smoking and either serological or clinical influenza was found, although the risk for serological influenza was slightly (not significantly) elevated in smokers compared to non-smokers. A statistical interaction was found between smoking and vaccination when serological influenza was the outcome measure indicating that the efficacy of vaccination was greater in smokers than in non-smokers (comparison of model with and without interaction; likelihood ratio test, p < 0.0001). This finding is supported by a greater titre rise 3 weeks after vaccination for two out of four strains, but not by the antibody response after vaccination in previous studies on influenza and other infectious diseases. Also, this possible difference of immunogenicity is not reflected in a better protection for clinical influenza. The rise in antibody titre 3 weeks after vaccination was higher in smokers for A/Singapore/6/86 and B/Beijing/11/87, but not for the other two strains. Decline in titres after 5 months was similar for smokers and non-smokers. We conclude that smoking has no clinical or preventive significance for risk of influenza in the elderly.
1991 - 1992年流感季节期间,我们在荷兰南林堡的15个家庭医疗诊所研究了吸烟与以下方面的关系:(1)流感的发生;(2)流感疫苗接种的效果;(3)流感疫苗接种后的抗体反应。数据来自一项关于流感疫苗接种效果的随机双盲安慰剂对照试验,在试验开始10周后测量吸烟状况。共有1838名60岁及以上的受试者,其中1531名(321名吸烟者、1152名非吸烟者和58名雪茄/烟斗吸烟者)返回了吸烟问卷且之前未接种过疫苗,被纳入分析。主要结局指标包括:血清学流感(接种疫苗后3周和5个月之间抗体滴度增加四倍);根据荷兰哨点站标准,通过接种疫苗后10周和5个月邮政问卷中自我报告的症状确定的临床流感;接种疫苗后抗体对数滴度的增加以及5个月后的降低。未发现吸烟与血清学或临床流感之间存在关联,尽管与非吸烟者相比,吸烟者血清学流感的风险略有(但不显著)升高。当血清学流感作为结局指标时,发现吸烟与疫苗接种之间存在统计学交互作用,表明吸烟者接种疫苗的效果优于非吸烟者(比较有交互作用和无交互作用的模型;似然比检验,p < 0.0001)。这一发现得到了四株病毒中两株在接种疫苗后3周滴度升高幅度更大的支持,但在之前关于流感和其他传染病的研究中,接种疫苗后的抗体反应并未体现这一点。此外,这种可能的免疫原性差异在临床流感的更好保护方面并未体现出来。吸烟者接种疫苗后3周,A/新加坡/6/86和B/北京/11/87的抗体滴度升高幅度更高,但其他两株病毒并非如此。吸烟者和非吸烟者在5个月后滴度下降情况相似。我们得出结论,吸烟对老年人患流感的风险没有临床或预防意义。